Cascinu Stefano, Di Bartolomeo Maria, Lonardi Sara, Beretta Giordano, Fornaro Lorenzo, De Vita Ferdinando
Comprehensive Cancer Center, IRCCS Ospedale San Raffaele, Università Vita-Salute San Raffaele, Milan, Italy.
Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
Front Med (Lausanne). 2022 Dec 15;9:1002435. doi: 10.3389/fmed.2022.1002435. eCollection 2022.
Gastric cancer (GC) is recognized as one of the most common deadly malignancies worldwide and about 40-50% of patients present at diagnosis with an unresectable disease due to a locally advanced or already metastatic condition. Recently, therapeutic options for management of metastatic GC (mGC) have been approved allowing a potential improvement of patient cancer treatment response and also an establishment of a continuum of care for this aggressive disease. This report is the result of a literature review by an expert panel. The aim of this document is to provide evidence, wherever it is lacking, to provide expert opinion directed at strategic management of mGC, and in particular aspect at practical management where appropriate guidelines are not available. Treatment landscape with new therapeutic strategies for third line and beyond, role of imaging, prognostic factors, symptoms, and markers as well as the importance of multidisciplinary approach particularly the nutritional aspects are discussed.
胃癌（GC）是全球公认的最常见致命恶性肿瘤之一，约40%-50%的患者在诊断时因局部晚期或已发生转移而出现不可切除的疾病。最近，转移性胃癌（mGC）的治疗方案已获批准，有望改善患者的癌症治疗反应，并为这种侵袭性疾病建立连续的护理体系。本报告是一个专家小组进行文献综述的结果。本文档的目的是在缺乏证据的地方提供证据，针对mGC的战略管理提供专家意见，特别是在缺乏适当指南的实际管理方面。讨论了三线及以上新治疗策略的治疗格局、影像学的作用、预后因素、症状、标志物以及多学科方法的重要性，尤其是营养方面。
